A Pilot Study on the Efficacy of DTG Plus 3TC for Prophylaxis of Mother-to-child Transmission of HIV Infection in Pregnant Women Who Have Detectable Viral Load After 14 Weeks of Gestation
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Acronyms PREGNANCY
- 12 Sep 2023 Status changed from recruiting to completed.
- 03 Feb 2022 Planned End Date changed from 31 Jan 2023 to 30 Jun 2023.
- 03 Feb 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Mar 2023.